Trial Profile

Expanded Access With Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin Dependent Kinase-like 5 Deficiency Disorder

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ganaxolone (Primary)
Indications Seizures
Focus Expanded access; Therapeutic Use
Acronyms CDD
Sponsors Marinus Pharmaceuticals

Most Recent Events

20 Sep 2021 According to a Marinus Pharmaceuticals media release, the company has established this program for patients in the U.S. who may be eligible to receive access to ganaxolone during the review of the NDA.
16 Dec 2020 Status changed from planning to recruiting.
07 Dec 2020 According to a Marinus Pharmaceuticals media release, announced the launch of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com